NME2 and breast carcinoma: Of note, NME2 is an upstream regulator of CTSK, a protease primarily expressed in osteoclasts which is involved in ECM degradation and bone remodeling and has been found to be expressed in numerous cancers including breast carcinoma [82, 83].